Business Context and Reporting Period
This Form 8-K Current Report from Adial Pharmaceuticals, Inc. (ADIL) covers events occurring on September 17, 2026, regarding the Company's 2026 Annual Meeting of Stockholders. The filing details the approval of several corporate governance and equity incentive proposals, as well as the partial adjournment of the meeting pending regulatory approvals.
Key Financial Metrics
This filing is a current report regarding corporate governance and voting results; it does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial performance metrics.
Material Changes and Voting Results
At the Annual Meeting, 1,278,677 shares (48.7% of outstanding shares) were present, establishing a quorum. Stockholders approved the following proposals with overwhelming support:
- Director Elections: Cary J. Claiborne and Robertson H. Gilliland were elected as Class II directors, though both are expected to resign shortly after all proposals are fully approved.
- Accounting Firm: Ratification of CBIZ CPAs P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Authorized Shares: Amendment to the Certificate of Incorporation to increase authorized Common Stock from 100,000,000 to 500,000,000 shares.
- Warrant Exercise: Approval to issue up to 552,940 shares upon exercise of Series F warrants to comply with Nasdaq Listing Rule 5635(d).
- Equity Plans: Approval of Amendment No. 8 to the 2017 Equity Incentive Plan, the new 2026 Equity Incentive Plan, and the 2026 Employee Stock Purchase Plan (ESPP).
- Adjournment: Approval to adjourn the meeting to facilitate further solicitation for remaining proposals.
Proposals 3, 4, 5, and 6 received preliminary support exceeding requirements but were not formally voted on. The meeting was adjourned regarding these specific items to allow time for the Company to obtain conditional approval from Nasdaq for its Initial Listing Application.
Outlook, Risks, and Contingencies
Adjournment and Regulatory Approval: The primary contingency is the pending Nasdaq conditional approval for the Initial Listing Application. Without this, the Company cannot finalize the vote on Proposals 3, 4, 5, and 6. The adjourned meeting is scheduled to reconvene on October 1, 2026, at 8:30 a.m. Eastern Time.
Management Changes: The filing notes that the newly elected directors, Cary J. Claiborne and Robertson H. Gilliland, are expected to resign shortly after the full approval of all proposals, indicating a potential transition in the Board of Directors.
Shareholder Action: Stockholders who have already voted on the adjourned proposals (3, 4, 5, and 6) do not need to take further action unless they wish to change their vote.
Investor Verification Checklist
- Verify the status of the Nasdaq Initial Listing Application conditional approval to determine if the adjourned meeting will proceed as scheduled.
- Confirm the final resignation status of Directors Claiborne and Gilliland and the composition of the Board following the adjourned meeting.
- Review the Definitive Proxy Statement (filed August 24, 2026) for detailed terms of the 2017 Plan Amendment, 2026 Plan, and 2026 ESPP.
- Monitor the final voting results for Proposals 3, 4, 5, and 6 once the adjourned meeting concludes.